Issued Patents All Time
Showing 26–50 of 112 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 10206918 | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers | Thomas M. Cardillo, David M. Goldenberg | 2019-02-19 |
| 10179171 | RS7 antibodies | Zhengxing Qu, Hans J. Hansen, David M. Goldenberg | 2019-01-15 |
| 10143756 | Antibody-SN-38 immunoconjugates with a CL2A linker | Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg | 2018-12-04 |
| 10137196 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2018-11-27 |
| 10130626 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2018-11-20 |
| 10130718 | Antibody-drug conjugates and uses thereof | David M. Goldenberg | 2018-11-20 |
| 10064957 | Immunoconjugates with an intracellularly-cleavable linkage | Sung-Ju Moon, David M. Goldenberg | 2018-09-04 |
| 10034950 | Antibody-SN-38 immunoconjugates with a CL2A linker | Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg | 2018-07-31 |
| 9999668 | RS7 antibodies | Zhengxing Qu, Hans J. Hansen, David M. Goldenberg | 2018-06-19 |
| 9931417 | Antibody-SN-38 immunoconjugates with a CL2A linker | Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg | 2018-04-03 |
| 9855344 | Antibody-SN-38 immunoconjugates with a CL2A linker | Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg | 2018-01-02 |
| 9849176 | RS7 antibodies | Zhengxing Qu, Hans J. Hansen, David M. Goldenberg | 2017-12-26 |
| 9833511 | RS7 antibodies | Zhengxing Qu, Hans J. Hansen, David M. Goldenberg | 2017-12-05 |
| 9770517 | Anti-Trop-2 antibody-drug conjugates and uses thereof | David M. Goldenberg | 2017-09-26 |
| 9745380 | RS7 antibodies | Zhengxing Qu, Hans J. Hansen, David M. Goldenberg | 2017-08-29 |
| 9707300 | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites | Sung-Ju Moon, David M. Goldenberg, Chien-Hsing Chang | 2017-07-18 |
| 9700634 | Immunoconjugates with an intracellularly-cleavable linkage | Sung-Ju Moon, David M. Goldenberg | 2017-07-11 |
| 9694088 | Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer | William J. McBride, Nalini Sathyanarayan, Christine Mazza-Ferreira, David M. Goldenberg | 2017-07-04 |
| 9675706 | Immunoconjugates with an intracellularly-cleavable linkage | Sung-Ju Moon, David M. Goldenberg | 2017-06-13 |
| 9629926 | Antibody-SN-38 immunoconjugates with a CL2A linker | Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg | 2017-04-25 |
| 9522959 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2016-12-20 |
| 9499631 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2016-11-22 |
| 9492566 | Antibody-drug conjugates and uses thereof | David M. Goldenberg | 2016-11-15 |
| 9493573 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2016-11-15 |
| 9493574 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | David M. Goldenberg | 2016-11-15 |